Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $26,041.09 in Stock

Key Points

• Insider selling: Elizabeth Yeu Lin sold multiple small blocks (379 shares on Mar 18 at $68.71, plus sales on Mar 17 and 19), and director William J. Link sold 12,500 shares on Mar 16, reducing insider positions and potentially adding short‑term selling pressure.
• Financials & trading: Tarsus beat revenue estimates ($151.7M vs. $144.6M) but slightly missed EPS expectations (loss $0.20 vs. -$0.19), and shares traded down about 2.2% to $66.75 with a market cap near $2.84B and a 52‑week range of $38.51–$85.25.
• Outlook: Analysts are broadly constructive (average rating "Moderate Buy" and average price target $91.83) with notable bullish calls (Lifesci upgrade to Strong‑Buy, Barclays overweight $100, Oppenheimer $105), and institutional investors own roughly 90% of the stock.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 379 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total transaction of $26,041.09. Following the completion of the transaction, the insider owned 23,698 shares in the company, valued at approximately $1,628,289.58. The trade was a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Thursday, March 19th, Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $67.00, for a total transaction of $26,130.00.
• On Tuesday, March 17th, Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $69.42, for a total transaction of $26,032.50.

Tarsus Pharmaceuticals Trading Down 2.2%

Shares of NASDAQ:TARS traded down $1.49 on Thursday, reaching $66.75. 461,600 shares of the company traded hands, compared to its average volume of 672,393. The stock has a market capitalization of $2.84 billion, a P/E ratio of -41.20 and a beta of 0.55. The business's 50-day simple moving average is $69.36 and its 200 day simple moving average is $70.18. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 52 week low of $38.51 and a 52 week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The company had revenue of $151.67 million for the quarter, compared to analysts' expectations of $144.56 million. As a group, equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals News Roundup

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to "Strong‑Buy" and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is "Moderate Buy" and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

Wall Street Analysts Forecast Growth

TARS has been the subject of a number of analyst reports. Lifesci Capital raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Monday. Barclays started coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an "overweight" rating and a $100.00 price target for the company. Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. The Goldman Sachs Group reissued a "neutral" rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Finally, Guggenheim boosted their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $91.83.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. RTW Investments LP increased its stake in shares of Tarsus Pharmaceuticals by 5.0% during the fourth quarter. RTW Investments LP now owns 3,335,320 shares of the company's stock valued at $273,096,000 after buying an additional 157,884 shares during the period. Deep Track Capital LP raised its holdings in shares of Tarsus Pharmaceuticals by 71.4% during the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company's stock valued at $178,290,000 after acquiring an additional 1,250,000 shares in the last quarter. Jennison Associates LLC lifted its stake in Tarsus Pharmaceuticals by 5.5% in the third quarter. Jennison Associates LLC now owns 2,604,580 shares of the company's stock worth $154,790,000 after acquiring an additional 136,582 shares during the period. Vanguard Group Inc. boosted its holdings in Tarsus Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company's stock valued at $196,476,000 after acquiring an additional 127,470 shares in the last quarter. Finally, Morgan Stanley boosted its holdings in Tarsus Pharmaceuticals by 6.7% in the fourth quarter. Morgan Stanley now owns 2,040,742 shares of the company's stock valued at $167,096,000 after acquiring an additional 128,340 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.